{"doi":"10.1128/jvi.01912-19","title":"Long-Acting Rilpivirine (RPV) Preexposure Prophylaxis Does Not Inhibit Vaginal Transmission of RPV-Resistant HIV-1 or Select for High-Frequency Drug Resistance in Humanized Mice","abstract":"The antiretroviral drug rilpivirine was developed into a long-acting formulation (RPV LA) to improve adherence for preexposure prophylaxis (PrEP) to prevent HIV-1 transmission. A concern is that RPV LA will not inhibit transmission of drug-resistant HIV-1 and may select for drug-resistant virus. In female humanized mice, we found that RPV LA inhibited vaginal transmission of WT or 3-fold RPV-resistant HIV-1 but not virus with 30-fold RPV resistance. In animals that became infected despite RPV LA PrEP, WT HIV-1 dissemination was delayed until genital and plasma RPV concentrations waned. RPV resistance was detected at similar low frequencies in untreated and PrEP-treated mice that became infected. These results indicate the importance of maintaining RPV at a sustained threshold after virus exposure to prevent dissemination of HIV-1 after vaginal infection and low-frequency resistance mutations conferred low-level resistance, suggesting that RPV resistance is difficult to develop after HIV-1 infection during RPV LA PrEP.","journal":"Journal of Virology","year":2020,"id":88762,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":9,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.961,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":449534,"name":"Chandra Nath Roy","orcid":"0000-0001-6667-1550","position":1,"is_corresponding":false},{"id":449413,"name":"Christopher E. Kline","orcid":"0000-0003-1025-9430","position":2,"is_corresponding":false},{"id":370688,"name":"Mackenzie L. Cottrell","orcid":"0000-0002-0291-5111","position":3,"is_corresponding":false},{"id":412226,"name":"Dwayne Evans","orcid":"0000-0003-0962-6838","position":4,"is_corresponding":false},{"id":356081,"name":"Kathleen A. Shutt","orcid":"0000-0003-3376-6152","position":5,"is_corresponding":false},{"id":369692,"name":"Pleuni S. Pennings","orcid":"0000-0001-8704-6578","position":6,"is_corresponding":false},{"id":233486,"name":"Brandon F. Keele","orcid":"0000-0002-2381-1151","position":7,"is_corresponding":false},{"id":449535,"name":"Moses T. Bility","orcid":"0000-0001-5153-2718","position":8,"is_corresponding":false},{"id":370695,"name":"Angela D. M. Kashuba","orcid":"0000-0002-9171-8493","position":9,"is_corresponding":false},{"id":307291,"name":"Zandrea Ambrose","orcid":"0000-0002-8610-2766","position":10,"is_corresponding":false},{"id":242850,"name":"Kevin Melody","orcid":"0000-0003-2713-5338","position":0,"is_corresponding":true}],"reference_count":87,"raw_metadata":null,"created_at":"2026-07-18T22:01:22.387926Z","pmid":"31969438","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}